Becton, Dickinson and Company Q3 Earnings Call Highlights

Impact · against what's priced in

BDX shows positive momentum through GLP-1 exposure and a raised EPS outlook, though long-term revenue is tempered by a structural headwind from Alaris remediation in 2027. Immediate positive catalysts are driven by strong cash flow and double-digit growth in biologics.

BDX+0.40

No priced-in read yet

In context

The company raised its full-year adjusted EPS outlook to $12.62-$12.72 and secured ~100 GLP-1 program agreements, offsetting a predicted 200-basis-point revenue headwind for 2027 due to Alaris remediation.

Read from the article alone

• BDX▲133%
• earnings
• guidance
• healthcare
• biosimilars
• glp 1
• medical devices
• medtech
• pharmacy automation